LEOPARD syndrome, also known as Gorlin syndrome II, cardiocutaneous syndrome, lentiginosis profusa syndrome, Moynahan syndrome, was more recently coined as Noonan syndrome with multiple lentigines (NSML), inside the RASopathies. Historically, the acronym LEOPARD refers to the presence of distinctive clinical features such as: lentigines (L), electrocardiographic/conduction abnormalities (E), ocular hypertelorism (O), pulmonary stenosis (P), genital abnormalities (A), retardation of growth (R), and sensorineural deafness (D). This condition is identified in 85% of patients with phenotype hallmarks caused by presence a germline point mutation in PTPN11 gene. Association of melanoma to NSML seems to be rare: to our knowledge, two patients so far were reported in the literature. We herein present a patient diagnosed with LEOPARD syndrome, in whom molecular investigation confirmed the presence of the c.1403C>T mutation in exon 12 of the PTPN11 gene, who developed four superficial spreading melanomas and three atypical lentiginous hyperplasias. Three of the melanomas were achromic or hypochromic, three were in situ, and one had a Breslow index under 0.5 mm. Dermoscopic examination showed some characteristic white structures in most of the lesions, which were a signature pattern and a key for the diagnosis. Histopathology and immunostaining (Pan-melanoma cocktail and HMB45) confirmed the diagnosis of lentigo maligna in situ with regression. Although recommended treatment for in situ melanoma is excision with a 0.5 cm margin, the previous diffuse melanoma history led us to use the "slow-Mohs," also called the "spaghetti technique" [3] , suggested by some teams for the treatment of lentigo maligna melanoma. This allowed us to achieve complete surgical excision of the lesion.
Six months later, we observed four new lesions suggestive of melanoma at dermoscopic examination ( Figure 3 ). On two of them we found white lines again. One of the lesions was a lentigo maligna; the others were atypical lentiginous hyperplasias. Three of them were incompletely removed.
So many melanomas and atypical lentiginous hyperplasias with infra-clinic extension led us to think about other ways to prevent the relapses of the lesions. We suggested the application of imiquimod 5 days a week for 8 weeks on the concerned lesions [4] . This was successful in preventing relapses as after a follow-up period of three years, no more doubtful lesions could be found.
A missense mutation in the protein tyrosine phosphatase non-receptor type 11 (PTPN11) gene is identified in about 85% of the LS patients. PTPN11 encodes for the SRC Homology 2 (SHP-2), a cytoplasmic protein tyrosine phosphatase which regulates intracellular signaling of RAS pathway downstream of receptors for growth factors, cytokines and hormones responsible for the development of NSLM [1, 2] . Missense change in NSLM is responsible for conformational switch that leaves the protein in an active state but with unexpected decreased phosphatase activity.
We herein report a LS patient with multiple melanomas.
Case
A 62-year-old man was referred to our clinic for a lesion of the upper foot, which had already been biopsied. Pathologic examination showed mild atypical melanocytes.
On physical examination, he had a high number of flat, brown to dark brown, small macules symmetrically distributed over a large portion of the skin, including the face. This case report enhances the importance of careful skin examination in LS patients.
As a result of the multiple melanomas found in this patient and his positive family history, we looked for a mutation of the CDKN2a gene, which was not found.
Discussion
We report the first case of a LEOPARD patient with multiple melanomas. Two previous LEOPARD patients with melanoma have been described: a 62-year-old woman, who developed a melanoma with a somatic BRAF mutation on top of her germline PTPN11 gene mutation [5] and a 24-year-old patient who suffered from a scalp melanoma [6] .
LS patients could present a higher risk for melanomas.
Indeed, it has been suggested that, although SHP2, the protein encoded by PTPN11, acts usually as an oncogene, it could also, in specific cell types, act as a tumor suppressor [7] . This has been shown in hepatocellular carcinogenesis: deletion of SHP2 promotes malignant transformation through the Stat3 pathway [8] . Stat3 pathway is also important in melanoma genesis, and deletion of PTPN11/SHP2 could therefore promote survival of malignant cells, metastasis, angiogenesis and immune evasion [7] .
On most of the melanomas we found a dermoscopic signature pattern: in the negative pigment network, the white lines showed thickening at their crossings. This pattern was very useful for diagnosing the clinically difficult melanomas
